Does Zepbound Cause Muscle Weakness?
Zepbound (tirzepatide) does not typically cause muscle weakness as a direct adverse effect, but rare cases of rhabdomyolysis—a severe muscle breakdown condition that can present with muscle pain, weakness, and dark urine—have been reported in the literature.
Understanding the Muscle-Related Risks
The FDA drug label for Zepbound does not list muscle weakness as a recognized adverse effect 1. However, emerging case reports from 2025-2026 document rare instances of tirzepatide-induced rhabdomyolysis, which can manifest as muscle weakness alongside other symptoms 2, 3, 4.
Documented Cases of Rhabdomyolysis
Three published case reports describe rhabdomyolysis following tirzepatide initiation:
- A 34-year-old HIV-positive male developed fatigue, muscle aches, and dark urine within 2 weeks of starting tirzepatide, with significantly elevated creatine kinase (CK) levels 2
- A 68-year-old man with type 2 diabetes and chronic kidney disease showed marked CK elevation after tirzepatide initiation, which normalized rapidly after discontinuation 3
- A 66-year-old woman experienced weakness, nausea, and markedly elevated CK after dose escalation 4
All cases resolved with tirzepatide discontinuation and supportive care, and the temporal relationship strongly suggested drug causation 2, 3, 4.
Effects on Muscle Mass vs. Muscle Function
It's critical to distinguish between muscle mass changes and muscle weakness:
Muscle Composition Changes
The SURPASS-3 MRI substudy found that tirzepatide treatment was associated with:
- Reductions in muscle fat infiltration (improved muscle quality)
- Reductions in muscle volume proportional to overall weight loss
- Muscle volume changes similar to population-based estimates for equivalent weight loss
- No evidence of disproportionate muscle loss or functional impairment 5
A 2025 systematic review confirmed that tirzepatide reduces fat mass while maintaining relative preservation of lean mass, with muscle composition indicators remaining stable or showing improvement 6.
Clinical Implications and Monitoring
When to Suspect Rhabdomyolysis
Monitor for these warning signs, especially during the first few weeks after initiation or dose escalation:
- Unexplained muscle pain, tenderness, or weakness
- Fatigue disproportionate to baseline
- Dark-colored urine (myoglobinuria)
- Nausea and vomiting
High-Risk Populations
Exercise heightened vigilance in:
- HIV-positive patients (may have increased risk for muscular disorders) 2
- Patients with chronic kidney disease 3
- Those on concurrent medications that affect muscle metabolism
Recommended Action
If rhabdomyolysis is suspected:
- Immediately check CK levels, renal function, and urinalysis for myoglobin
- Discontinue tirzepatide
- Initiate aggressive intravenous fluid therapy
- Monitor for acute kidney injury
Context from Guidelines
Current diabetes guidelines 7, 8 do not identify muscle weakness as a concern with tirzepatide or other GLP-1/GIP receptor agonists. The primary documented adverse effects remain gastrointestinal symptoms, which are comparable to other agents in this class 9.
The overall safety profile of tirzepatide remains favorable, with rhabdomyolysis representing an extremely rare but serious potential complication that requires clinical awareness 3, 4.